今月の研究者

今月の研究者

鈴木　文孝

鈴木　文孝

【キャリア】
1988年弘前大学医学部卒業後、浜松医大第二内科に入局しました。その後、県西部浜松医療センター消化器科、浜松医大第二内科で勤務後、1993年に1年間虎の門病院肝臓内科に勤務しました。この1年間でウイルス性肝炎の最新の治療法を学ぶとともに、茶山一彰先生（現広島大学教授）より遺伝子解析の研究についてご指導いただきました。その後浜松医大第二内科、県西部浜松医療センター消化器科勤務を経て、1999年より虎の門病院肝臓内科に勤務し、2011年4月より肝臓内科部長として現在に至っています。

【研究分野】
現在までの私の研究は、B型肝炎、C型肝炎の抗ウイルス療法の治療成績をまとめるとともに、肝炎ウイルスの遺伝子変異（特に薬剤耐性ウイルス）が治療効果や病態にどのように関係するかを調べてきました。また、生体側のゲノム（SNPs）と肝炎の病態や抗ウイルス治療との関係、肝組織を用いたウイルス量(cccDNA, total DNA量)の測定などの研究も行ってきました。

【今後の抱負・アピール】
C型肝炎に対する抗ウイルス剤の進歩は急速であり、多くの症例でSVR（治癒）
が得られています。一方B型肝炎の持続感染者は、日本には100－150万人いると言われていますが、一度感染したHBVは肝細胞内から除去することはできません。B型肝炎に対するより効果的な治療法と治療効果に関係するウイルス側、生体側因子を新たな手法も取り入れながら解析し、将来的な医療・医学の進歩に少しでも貢献できればと考えています。またNASH,NAFLDのような代謝性疾患に関係する肝疾患も増加しています。ウイルス肝炎と同様に基礎的な研究を含めた解析が今後必要を考えています。

発表・論文

主な研究業績論文

1. Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, and Hiromitsu Kumada H. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastoroenterol 2016 (in press)

2. Suzuki F, Sezaki H,Akuta N, Suzuki Y,Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzki Y, Kumada H. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. Drug Desgin, Development and Therapy 2014(8): 869-873.

3. Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.J Gastroenterol. 2014;49(6):1094-1104.

4. Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.Hepatol Res. 2013;43(7):691-701.

5. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54(4):352-4.

6. Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Ikeda K, Kobayashi M, Kumada H. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol. 2012;47(7):814-22.

7. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Nakamura Y, Miyakawa Y, Kumada H. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011:53;415-421.

8. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol. 2010;25(5):892-8.

9. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol. 2010;47(1):76-8.

10. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Yatsuji H, Kawamura Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kobayashi M, Miyakawa Y, Kumada H. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res. 2009;39(11):1056-63.

11. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81(1):27-33.

12. Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol. 2008;23(9):1320-6.

13. Suzuki F, Kumada H. Interferon and lamivudine monotherapy on chronic hepatitis B in Japan. Hepatol Res. 2007;37(s1):S42-6.

14. Suzuki F, Suzuki Y, Akuta N, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H. Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. Hepatol Res. 2008;38(2):132-40.

15. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol. 2007;39(2):149-52.

16. Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol. 2006;78(8):1025-34.

17. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol. 2006;78(3):341-52.

18. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Kumada H. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol. 2004;39(10):969-74.

19. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat. 2004;11(3):271-6.

20. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology. 2003;46(3):182-9.

21. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B. J Med Virol. 2003;70(3):355-60.

22. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol. 2002;37(11):922-7.

23. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol. 2002;37(6):824-30.

24. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Pathogenic significance and organic virus levels in patients infected with TT virus. Intervirology. 2001;44(5):291-7.

25. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol. 2001;36(4):242-7.

▲

Copyright © 2024 冲中記念成人病研究所 All Rights Reserved.